Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of paltusotine in acromegaly patients not receiving medical therapy
CTR20222370Phase 3Terminated
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing Paltusotine with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving biochemical IGF-1 response at end of randomized controlled phase. Started Mar 2023; status: terminated.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20222370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222370.